Latest news for Worldline (OTC:WWLNF) Stock

Worldline is a payment service provider offering merchant acquiring, payment processing, and payment infrastructure solutions to merchants and banks.

Earnings

News

Movers

Tech

Media

Trading Ideas

WRDLY

WWLNF

Apollo Global Management Inc (NYSE: APO) is close to acquiring the point-of-sale terminal business of European payments company Worldline SA (OTC: WRDLY) (OTC: 

Apollo Global Management Nears Acquisition Of Worldline; Cuts Quarterly Dividend After Q4 Consensus Miss

Intraday Update

Markets

AACTF

ABBRF

ADBE

ADUS

AEHR

AFGC

AGNC

AMXEF

AMXVF

APPF

APPN

APTO

ARCAY

ARCE

ARCVF

ASHTY

ASNB

ATGFF

ATRC

ATVI

AZRE

BCYC

BILI

BLDP

BOWFF

BURL

BWXT

BXMT

CDLX

CDPYF

CEVA

CFBK

CFFA

CLGX

CLHRF

CLPBF

CLPBY

CMCLF

CMLEF

CMXHF

CNNE

COST

CPRT

CPWHF

CTAS

CTXXF

CWEN

CWEN-A

CWST

DBOEY

DIMC

DLT RESOLUTION INC by DLT Resolution Inc.

DLTI

DNNGY

DOCU

DOOR

DRTGF

EDPFY

Stocks That Hit 52-Week Highs On Tuesday

Worldline SA

UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) analysts stay mostly on the sidelines with concerns for the short-term after the company reported third-quarter financial results Thursday.
The PATH Analysts: Oppenheimer analyst Brian Schwartz maintained a Perform rating on UiPath with no price target.
RBC Capital Markets analyst Matthew Hedberg maintained a Sector Perform rating with a $16 price target.
Truist analyst Terry Tillman maintained a Hold rating with a $14 price target.
KeyBanc Capital Markets analyst Jason Celino maintained a Sector Weight rating with no price target.
JPMorgan analyst Mark Murphy maintained an Overweight rating and raised the price target from $17 to $18.
Oppenheimer on PATH: Management commentary could suggest that stabilization is expected for the company next year, Schwartz said in a new investor note.
The analyst said margin growth returning and guidance for faster free cash flow growth are positives from the quarter. The negatives were soft guidance, modest billings growth and declining net new ARR (annual recurring revenue) trends, the analyst added.
"F3Q results and guidance are unlikely to alleviate investor concerns that AI is weakening the company's moat," Schwartz said.
RBC Capital on PATH: The quarterly results showed improved execution and a stable demand environment Hedberg said in a new investor note.
The analyst highlighted the company's commentary on stabilized net new ARR in the report.
"We continue to believe PATH is likely to remain range-bound over the medium term and as execution improvement plays out and the agent vision unfolds," Hedberg said.
Hedberg highlighted UiPath's commentary on early interest from customers with over 1,000 sign-ups for the Agent Builder product.
"While we like the agent vision and improved execution, we think it will take some time to see tangible benefits from agentic solutions, and we'd like to see more proof points of stability in results."
Truist on PATH: The company's growth remains sluggish going forward, Tillman said in a new investor note.
"The story remains a work in progress in terms of improving annualized renewal run-rate and returning net new ARR to a position of solid growth," Tillman said.
The analyst said the company showed progress in the third quarter with advancing partnerships and early adoption of its agentic automation.
"Sustained execution improvement remain key to growth reacceleration, in our opinion."
KeyBanc on PATH: Initial fiscal 2026 commentary was more mixed than expected, Celino said in a new investor note.
The analyst said the commentary that net new ARR dollars are expected to stabilize could be viewed as a downtick versus consensus estimates of a modest uptick.
"In terms of macro, UiPath noted trends remain largely consistent with no noticeable signs of improvements or deterioration," Celino said.
Celino said there could be long-term opportunities, but the near-term execution and growth challenges remain near-term concerns.
JPMorgan on PATH: The company showed a positive tone with its outlook and commentary, Murphy said in a new investor note.
The analyst said the company's Second Act is centered on the Agentic Model.
"UiPath appears to be making bold moves and speaking very confidently to its Agentic vision, conveying an ability to up-level conversations with customers and elevating its platform beyond just automation," Murphy said.
The new platform could open up the company for "new growth vectors," the analyst said.
"Overall, we view the performance in the quarter as solid, and see the business as mostly stable/stabilizing."
PATH Price Action: UiPath stock is down 2.47% to $14.58 on Friday versus a 52-week trading range of $10.37 to $27.87. The stock is down 39% year-to-date in 2024.
Read Next: • <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42363278/us-economy-adds-227000-jobs-in-november-wage-growth-accelerates">US Economy Adds 227,000 Jobs In November, Wage Growth Accelerates</a>
Photo: Courtesy of UiPath, Inc.

Analyst Color

Guidance

Price Target

Reiteration

Analyst Ratings

PATH

UiPath 'Story Remains A Work In Progress': Analysts Want To See More After Q3 Results, 'Sustained Execution Remains Key'

Stephens &amp; Co. analyst Sudan Loganathan reiterates Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) with a Overweight and maintains $5 price target.

ELEV

Stephens & Co. Reiterates Overweight on Elevation Oncology, Maintains $5 Price Target

<a href="https://x.com/TikTokPolicy/status/1865080490161492208" title="https://x.com/TikTokPolicy/status/1865080490161492208">https://x.com/TikTokPolicy/status/1865080490161492208</a> &nbsp;

Macro Notification

General

GOOG

GOOGL

ORCL

PINS

SNAP

Tiktok Says It Expects U.S. Supreme Court To Reverse Appeals Court Decision

BMO Capital analyst Keith Bachman maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Market Perform and raises the price target from $15 to $16.

BMO Capital Maintains Market Perform on UiPath, Raises Price Target to $16

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares are moving higher on Friday after the company reported better-than-expected 2024 third-quarter earnings on Thursday <a href="https://www.benzinga.com//node/42351981">after the market closed</a>.
The Details: Ulta shares traded about 10% higher after the bell on Thursday following the release of the company&#8217;s earnings report. The earnings report included adjusted earnings per share of $5.14, beating analyst estimates of $4.54. 
In addition, the company reported sales of $2.53 billion, beating analyst estimates of $2.50 billion. Comparable sales for the quarter were up 4.5% year-over-year which the company attributed to a&nbsp;0.5%&nbsp;increase in transactions and a&nbsp;0.1%&nbsp;growth in average ticket.
Ulta reported other important pieces of financial information. The company reported selling, general and administrative expenses of $682.3 million and operating income of $318.5 million. Additionally, it reported cash and cash equivalents of $177.8 million.
The company repurchased 731,458 shares during the third quarter. Furthermore, it has approximately $2.9 billion remaining in authorized share repurchases.
Ulta raised its guidance for the 2024 fiscal year. Previously the company expected net sales from $11.0 billion to $11.2 billion. Ulta now expects between $11.1 billion to $11.2 billion versus analyst estimates of $11.17 billion.
Analyst Changes: Following the earnings report, multiple analysts issued <a href="https://www.benzinga.com/quote/ULTA/analyst-ratings">price target adjustments</a>.
<ul>
<li>Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating on Ulta and raised the price target from&nbsp;$450&nbsp;to&nbsp;$500.</li>
<li>Canaccord Genuity analyst Susan Anderson maintained a Buy rating on Ulta and raised its price target from $476 to $500.</li>
<li>Piper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating on Ulta and raised its price target from $360 to $390.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Underweight rating on Ulta and raised its price target from $300 to $350.</li>
<li>Stifel analyst Mark Astrachan maintained a Hold rating on Ulta and raised its price target from $395 to $455.</li>
</ul>
Related Link:<a href="https://www.benzinga.com/general/restaurants/24/12/42367360/shaped-by-kevin-miles-legacy-at-zoes-kitchen-this-mediterranean-restaurant-chain-is-rising-fast-as-a-chipotle-killer-whats-making-it-tick"> Shaped By Kevin Miles&#8217; Legacy At Zoës Kitchen, This Mediterranean Restaurant Chain Is Rising Fast As A Chipotle Killer: What&#8217;s Making It Tick?</a>
ULTA Price Action: At the time of writing, Ulta shares are trading 10.60% higher at $434.50, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Wikimedia Commons

ULTA

What's Going On With Ulta Beauty Stock Friday?

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) on Friday crossed the $4,000 threshold for the first time since March, signaling renewed investor confidence as institutional interest in <a href="https://www.benzinga.com/money/ethereum-eth-price-predictions#:~:text=According%20to%20its%20analysis%2C%20Ether's,and%20reaching%20%2424%2C190.96%20by%202030.">the cryptocurrency grows</a>.
The surge is closely tied to record-breaking inflows into U.S. Ethereum spot ETFs, which have simplified access to the asset for institutional players.
On Dec. 5, <a href="https://www.benzinga.com/money/what-is-ethereum-etf">Ethereum spot ETFs</a> reported an unprecedented total net inflow of $428 million.
BlackRock&#8216;s Ethereum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>) led with $293 million in daily net inflows, followed by Fidelity's Ethereum ETF (CBOE: FETH), which saw $114 million in inflows. 
These figures demonstrate the accelerating adoption of Ethereum as an asset class within traditional financial markets.
Ethereum, now trading around $4,007, up 3.5% over the last 24 hours. 
Prediction markets reflect mixed but cautiously optimistic sentiment regarding Ethereum's near-term price trajectory. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42365154/bitcoin-reserve-would-benefit-special-interest-groups-former-fed-chairman-warns">Bitcoin Reserve Would &#8216;Benefit Special Interest Groups,&#8217; Former Fed Chairman Warns</a>
<a href="https://polymarket.com/event/ethereum-all-time-high-in-2024?tid=1733497822487">According </a>to Polymarket data:
<ul>
<li>Bettors assign a 41% probability to Ethereum reaching a new all-time high by the end of 2024, indicating moderate confidence in its growth potential.</li>
<li>For December specifically, bettors estimate:
<ul>
<li>A 26% chance that Ethereum will hit $5,000.</li>
<li>A 53% likelihood of crossing $4,500.</li>
<li>A 62% probability of reaching $4,300.</li>
<li>A 78% chance that Ethereum will maintain prices above $4,200.</li>
</ul>
</li>
</ul>
Polymarket's trading volumes further validate Ethereum's strong performance. 
The market for Ethereum's year-end price movements has amassed over $1.6 million in volume, indicating substantial interest among traders and bettors. 
The <a href="https://polymarket.com/event/what-price-will-ethereum-hit-in-december">question</a> of whether Ethereum will reach a new all-time high by the close of 2024 has garnered significant attention, with trading volumes surpassing $8.5 million for this market alone.
Ethereum's ability to surpass $4,000 is reflective of a broader recovery in the cryptocurrency market. 
However, it remains approximately 17% below its all-time high of $4,878, last recorded <a href="https://www.benzinga.com/news/24/12/42316845/ethereum-soars-50-in-a-month-as-trader-forecasts-a-legendary-breakout-south-korean-president-yoon-suk-yeol-faces-impeachment-calls-following-a-short-lived-martial-law-top-headlines-today-while">in November 2021.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42362590/semler-scientific-expands-bitcoin-holdings-to-over-180-million-with-latest-purchase">Semler Scientific Expands Bitcoin Holdings To Over $180 Million With Latest Purchase</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

ETHA

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

Ethereum Breaks $4,000: Could It Make A New All-Time High In 2024?

BMO Capital analyst Keith Bachman maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Outperform and raises the price target from $38 to $72.

RBRK

BMO Capital Maintains Outperform on Rubrik, Raises Price Target to $72

NAMI

Jinxin Technology Holding Company Shares Resume Trading; Quickly Halted To The Upside; Now Up 81.50%

BMO Capital analyst Simeon Siegel maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Market Perform and raises the price target from $385 to $420.

BMO Capital Maintains Market Perform on Ulta Beauty, Raises Price Target to $420

BMO Capital analyst Simeon Siegel maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Outperform and raises the price target from $33 to $46.

VSCO

BMO Capital Maintains Outperform on Victoria's Secret, Raises Price Target to $46

<a href="https://www.paramountpressexpress.com/cbs-news-and-stations/shows/60-minutes/releases/?view=110721-90-minutes-of-60-minutes-this-sunday-dec-8" title="https://www.paramountpressexpress.com/cbs-news-and-stations/shows/60-minutes/releases/?view=110721-90-minutes-of-60-minutes-this-sunday-dec-8">https://www.paramountpressexpress.com/cbs-news-and-stations/shows/60-minutes/releases/?view=110721-90-minutes-of-60-minutes-this-sunday-dec-8</a>

Events

Watching Boeing; Shares See Volume To The Downside As Traders Circulate CBS Publication Of 90 Minutes Of "60 Minutes" This Sunday, Dec. 8 With 'Boeing's Whistleblowers' As One Of Its Segments

BMO Capital analyst John Kim downgrades Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) from Market Perform to Underperform and lowers the price target from $120 to $104.

Downgrades

BMO Capital Downgrades Prologis to Underperform, Lowers Price Target to $104

Biotech

STOK

Stoke Therapeutics Reports New OLE Study Data Highlighting Zorevunersen's Potential as a Disease-Modifying Treatment for Dravet Syndrome; Significant Seizure Reductions and Cognitive Improvements Observed Over 2 Years

BMO Capital analyst Juan Sanabria upgrades Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) from Market Perform to Outperform and raises the price target from $30 to $33.

Upgrades

BMO Capital Upgrades Brixmor Property Group to Outperform, Raises Price Target to $33

Management

BMRC

Bank of Marin Bancorp CFO Tani Girton to Retire January 2025; Treasurer Dave Bonaccorso Named Successor Effective January 2

<a href="https://www.clevelandfed.org/collections/press-releases/2024/pr-20241206-presidents-speech-fourth-district-on-economy-and-monetary-policy" title="https://www.clevelandfed.org/collections/press-releases/2024/pr-20241206-presidents-speech-fourth-district-on-economy-and-monetary-policy">https://www.clevelandfed.org/collections/press-releases/2024/pr-20241206-presidents-speech-fourth-district-on-economy-and-monetary-policy</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Hammack Says Monetary Policy Likely 'Somewhat Restrictive'; Fed Has More Work To Do To Cool Inflation; Economy Is Strong, Labor Market Is Healthy; Labor Market Has Become Better Balanced

RAPP

Rapport Therapeutics Highlights Data Linking 30% Reduction in Long Episodes to Over 50% Seizure Reduction, Validating Biomarker for Phase 2a Focal Epilepsy Trial With Topline Results Expected Mid-2025

Fed's Hammack Says Fed 'At Or Near' Time To Slow Pace Of Rate Cuts; 'Open Mind' About December Fomc Meeting, More Data Incoming; Market View Of One Cut Between Now And Late January Reasonable; Slowing Pace Of Rate Cuts Allows Fed Time To Sound Economy; Economic Landscape Calls For 'modestly Restrictive' Monetary Policy; Expects Solid Growth, Low Unemployment, Gradual Inflation Ebbing; Data Will Drive What Fed Does With Monetary Policy

BMO Capital analyst Ketan Mamtora upgrades Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and maintains the price target from $38 to $38.

BMO Capital Upgrades Weyerhaeuser to Outperform, Maintains Price Target to $38

During the last three months, 9 analysts shared their evaluations of Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.67, a high estimate of $41.00, and a low estimate of $26.00. This upward trend is evident, with the current average reflecting a 11.12% increase from the previous average price target of $28.50.
<img src="https://www.benzinga.com/files/images/story/2024/1733504466_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Nurix Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Roger Song</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nurix Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Nurix Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NRIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nurix Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Nurix Therapeutics</h2>
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
<h3>Nurix Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Nurix Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 31 August, 2024, the company experienced a revenue decline of approximately -31.84%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nurix Therapeutics's net margin excels beyond industry benchmarks, reaching -388.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Nurix Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.1%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Nurix Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.56%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Nurix Therapeutics's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NRIX

Decoding 9 Analyst Evaluations For Nurix Therapeutics

Worldline SA 2024 Q2 - Results - Earnings Call Presentation

Worldline SA (WWLNF) H1 2024 Earnings Call Transcript

Positive digital euro news boosts EU payment stocks, hits U.S. counterparts, study finds

Comments

Worldline

News

Latest news for Worldline (OTC:WWLNF) Stock

Friday, February 11, 2022

Tuesday, February 18, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga